Robert Dengler

958 total citations
21 papers, 209 citations indexed

About

Robert Dengler is a scholar working on Cancer Research, General Health Professions and Oncology. According to data from OpenAlex, Robert Dengler has authored 21 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cancer Research, 7 papers in General Health Professions and 7 papers in Oncology. Recurrent topics in Robert Dengler's work include Health and Medical Studies (5 papers), Medical Practices and Rehabilitation (4 papers) and Medical and Health Sciences Research (4 papers). Robert Dengler is often cited by papers focused on Health and Medical Studies (5 papers), Medical Practices and Rehabilitation (4 papers) and Medical and Health Sciences Research (4 papers). Robert Dengler collaborates with scholars based in Germany, Spain and United States. Robert Dengler's co-authors include Bertold Emmerich, Stefan Faderl, Christoph Nerl, S. Al-Batran, Katharina Pachmann, Ulrich Pachmann, Matthias Rengsberger, Manfred Welslau, Bernd Weiß and Uirassu Borges and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and British Journal of Haematology.

In The Last Decade

Robert Dengler

20 papers receiving 199 citations

Peers

Countries citing papers authored by Robert Dengler

Since Specialization

Citations

This map shows the geographic impact of Robert Dengler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Dengler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Dengler more than expected).

Fields of papers citing papers by Robert Dengler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Dengler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Dengler. The network helps show where Robert Dengler may publish in the future.

Co-authorship network of co-authors of Robert Dengler

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Dengler. A scholar is included among the top collaborators of Robert Dengler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Dengler. Robert Dengler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany 2024 ·Cost Effectiveness and Resource Allocation ·(unknown), (unknown), (unknown), Luísa Camacho, (unknown), Florian Kron, Robert Dengler	1
2	Ambulante spezialfachärztliche Versorgung 2023 ·PUBLISSO (German National Library of Medicine) ·Robert Dengler, (unknown), (unknown), (unknown)	1
3	Ambulante spezialfachärztliche Versorgung (ASV) in der Thoraxonkologie 2023 ·Matthias Raspe, (unknown), Robert Dengler	0
4	Ambulante Spezialfachärztliche Versorgung (ASV): eine multiperspektivische Studie zu Status quo, Herausforderungen und Perspektiven 2022 ·Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen ·Robert Dengler, (unknown), (unknown), Jana Becker, (unknown), Oliver Riedel, Ulrike Haug, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
5	Vergütungsunterschiede bei der ambulanten spezialfachärztlichen Versorgung (ASV) im Vergleich zur bisherigen Behandlungsform. Eine explorative Analyse an drei Einrichtungen der Fachgruppe internistische Onkologie im Indikationsbereich gastrointestinale Tumoren 2019 ·Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen ·Robert Dengler, (unknown), Stefan Pluntke, Florian Kaiser, Stephan Schmitz	2
6	Zur Diskussion: Neustrukturierung der fachärztlichen Behandlung am Beispiel der ambulanten spezialfachärztlichen Versorgung (ASV): ein kritischer Blick auf Ziele und Umsetzung 2018 ·Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen ·Robert Dengler, (unknown)	3
7	Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial 2017 ·Supportive Care in Cancer ·(unknown), Bernd Weiß, Uirassu Borges, (unknown), Robert Dengler, (unknown), Manfred Welslau, (unknown)	24
8	Bereitschaft zur Teilnahme an der ambulanten spezialfachärztlichen Versorgung (ASV): eine kritische Bestandsaufnahme 2017 ·Das Gesundheitswesen ·Robert Dengler, (unknown), (unknown), (unknown)	3
9	Tumor Boards from the Perspective of Ambulant Oncological Care 2016 ·Oncology Research and Treatment ·(unknown), Robert Dengler, (unknown), (unknown)	3
10	Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: An increase in cell number at completion of therapy is a predictor of early relapse 2007 ·The Breast ·(unknown), (unknown), Matthias Rengsberger, (unknown), Robert Dengler, Ulrich Pachmann, Katharina Pachmann	29
11	An increase in cell number at completion of therapy may develop as an indicator of early relapse 2007 ·Journal of Cancer Research and Clinical Oncology ·Katharina Pachmann, Robert Dengler, (unknown), (unknown), Torsten Kroll, Matthias Rengsberger, (unknown), Ulrich Pachmann	24
12	Circulating tumor cells: Tools for monitoring and targets for therapy 2006 ·Journal of Clinical Oncology ·Katharina Pachmann, Oumar Camara, (unknown), Robert Dengler, Ingo B. Runnebaum, Klaus Hoeffken, Ulrich Pachmann	2
13	1000 Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in far advanced malignancies 2003 ·European Journal of Cancer Supplements ·A. Reichle, (unknown), Thomas Vogt, F Bataille, Peter J. Wild, Anna Berand, Frank Klebl, Stefan W. Krause, Robert Dengler, Reinhard Andreesen	2
14	Infiltration of the central nervous System by a granulosa cell tumor immunestained by antibodies against inhibin 1998 ·Neurology ·(unknown), B. Soudah, R von Wasielewski, Martijn de Groot, B. Haubitz, H. Becker, Robert Dengler	7
15	Limited Proteolysis of alpha₁-Proteinase Inhibitor (α₁-PI) in Acute Leukemia: Studies on the Resulting Fragments and Implication for the Structure of the Inactivated Inhibitor 1995 ·Biological Chemistry Hoppe-Seyler ·Robert Dengler, F. Lottspeich, Walter OBERTHÜR, Alan E. Mast, Bertold Emmerich	3
16	Urinary excretion of proteolyzed alpha1-antitrypsin: specificity, quantitation, and relation to therapy response in patients with acute myeloid leukemia. 1995 ·PubMed ·Robert Dengler, Andreas Plewan, (unknown), (unknown), (unknown), B. Emmerich	2
17	Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells 1995 ·British Journal of Haematology ·Robert Dengler, (unknown), S. Al-Batran, (unknown), Stefan Faderl, Christoph Nerl, Bertold Emmerich	85
18	Trisomy 21 as the sole clonal aberration in a patient with acute myelomonocytic leukemia with abnormal bone marrow eosinophils and extramedullary involvement 1994 ·Annals of Hematology ·Robert Dengler, (unknown), Bertold Emmerich	2
19	Proteolytic Inactivation of alpha₁-Proteinase Inhibitor in vivo: Detection, Characterization and Quantitation of the Main Fragment Excreted in the Urine of Leukemia Patients 1992 ·Biological Chemistry Hoppe-Seyler ·Robert Dengler, (unknown), F. Lottspeich, Andreas Plewan, Adaling Ogilvie, Bertold Emmerich	4
20	Detection of cathepsin B in tumor cytosol and urine of breast cancer patients. 1991 ·PubMed ·Robert Dengler, (unknown), (unknown), Vito Türk, Hans Fritz, Bertold Emmerich	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact